Wanbury gets Certificate of Suitability for cough relief medicine in Europe
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-09 09:31 GMT | Update On 2024-09-09 09:31 GMT
Advertisement
Maharashtra: Wanbury Limited has announced that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine.
The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. "With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets," the Compamy stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.